JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 121 filers reported holding JUNO THERAPEUTICS INC in Q1 2015. The put-call ratio across all filers is 1.68 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $4,286,000 | -2.9% | 93,773 | -4.7% | 0.01% | 0.0% |
| Q3 2017 | $4,413,000 | +1.4% | 98,399 | -32.4% | 0.01% | -16.7% |
| Q2 2017 | $4,354,000 | +29.9% | 145,663 | -3.6% | 0.01% | +33.3% |
| Q1 2017 | $3,351,000 | +21.1% | 151,030 | +2.9% | 0.01% | +12.5% |
| Q4 2016 | $2,766,000 | -29.7% | 146,738 | +11.9% | 0.01% | -33.3% |
| Q3 2016 | $3,936,000 | -11.3% | 131,150 | +13.6% | 0.01% | -14.3% |
| Q2 2016 | $4,436,000 | +1.6% | 115,404 | +0.7% | 0.01% | 0.0% |
| Q1 2016 | $4,364,000 | +5.5% | 114,570 | +21.7% | 0.01% | +16.7% |
| Q4 2015 | $4,138,000 | +341.6% | 94,109 | +308.9% | 0.01% | +300.0% |
| Q3 2015 | $937,000 | -90.3% | 23,017 | -87.3% | 0.00% | -87.5% |
| Q2 2015 | $9,637,000 | +111.0% | 180,703 | +140.0% | 0.02% | +118.2% |
| Q1 2015 | $4,568,000 | – | 75,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |